1. Home
  2. LCTX vs CLDT Comparison

LCTX vs CLDT Comparison

Compare LCTX & CLDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.95

Market Cap

366.2M

Sector

Health Care

ML Signal

HOLD

Logo Chatham Lodging Trust (REIT) of Beneficial Interest

CLDT

Chatham Lodging Trust (REIT) of Beneficial Interest

HOLD

Current Price

$7.83

Market Cap

362.9M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
LCTX
CLDT
Founded
1990
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
366.2M
362.9M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
LCTX
CLDT
Price
$1.95
$7.83
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
1
Target Price
$4.67
$9.50
AVG Volume (30 Days)
1.2M
225.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
4.86%
EPS Growth
25.00
N/A
EPS
N/A
N/A
Revenue
$9,499,000.00
N/A
Revenue This Year
$6.32
$1.39
Revenue Next Year
$124.49
N/A
P/E Ratio
N/A
$610.21
Revenue Growth
6.19
N/A
52 Week Low
$0.37
$5.83
52 Week High
$2.09
$8.47

Technical Indicators

Market Signals
Indicator
LCTX
CLDT
Relative Strength Index (RSI) 64.30 65.99
Support Level $1.55 $6.84
Resistance Level $2.04 N/A
Average True Range (ATR) 0.11 0.22
MACD 0.02 -0.01
Stochastic Oscillator 89.04 97.73

Price Performance

Historical Comparison
LCTX
CLDT

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

About CLDT Chatham Lodging Trust (REIT) of Beneficial Interest

Chatham Lodging Trust is a U.S.-based real estate investment trust that invests in upscale extended-stay hotels. The firm operates across various states in the U.S., including California, New York, Texas, Florida, Minnesota, Massachusetts, and Pennsylvania among others. Substantially all of the company's assets are held and operated by its Operating Partnership, Chatham Lodging, LP. Chatham Lodging LP and its subsidiaries lease the overall company's hotels. The firm operates through a single segment because of the similar economic characteristics of its hotels. Chatham's revenue streams include Room, Food and beverage, and Other. Room comprises the majority of total revenue. Chatham's hotels operate under brands which include, Hilton, Marriott, and Hyatt.

Share on Social Networks: